BioNTech SE (NASDAQ:BNTX) is included among the 10 Best Global Stocks to Buy According to Wall Street Analysts. BioNTech SE ...

Earlier in April 2026, BioNTech reported positive primary Phase 2 results for its HER2‑targeted antibody-drug conjugate trastuzumab pamirtecan in previously treated, advanced endometrial cancer, ...

BioNTech SE Sponsored ADR (BNTX) shares ended the last trading session 6.1% higher at $111.6. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2026 on Tuesday, May 5, 2026. Additionally, the Company will host a conference call ...

The Phase II cohort analysis included 145 patients whose conditions had progressed following initial chemotherapy.

CureVac, now owned by BioNTech, has filed an eight-patent infringement lawsuit against Moderna in Delaware, alleging Spikevax ...

The drug candidate, Trastuzumab Pamirtecan, also holds both FDA Fast Track and Breakthrough Therapy designations. Phase 3 trials are underway, and a Biologics License Application is planned for 2026.

A significant insider sale has injected a note of caution into BioNTech's recent rally, as Chief Operating Officer Sierk Poetting unloaded 50,000 shares just days before the company's critical ...

Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall ...

Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of heavily pre-treated patients with HER2-expressing, recurrent ...